Drug Type Mesenchymal stem cell therapy |
Synonyms hALDMSC Promethera, HepaStem, Heterologous Human Adult Liver derived Progenitor Cells + [1] |
Target- |
Action stimulants |
Mechanism Cartilage replacements, Cell replacements, Osteogenesis stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Liver Cirrhosis | Phase 2 | Belgium | 30 Jan 2022 | |
Nonalcoholic Steatohepatitis | Phase 2 | Poland | 02 Jan 2019 | |
liver function failure | Phase 2 | Belgium | 30 Mar 2016 | |
liver function failure | Phase 2 | Bulgaria | 30 Mar 2016 | |
liver function failure | Phase 2 | France | 30 Mar 2016 | |
liver function failure | Phase 2 | Spain | 30 Mar 2016 | |
Ornithine Carbamoyltransferase Deficiency Disease | Phase 2 | Belgium | 01 Jul 2014 | |
Ornithine Carbamoyltransferase Deficiency Disease | Phase 2 | France | 01 Jul 2014 | |
Urea Cycle Disorders, Inborn | Phase 2 | Portugal | 19 Mar 2013 | |
Citrullinemia | Phase 2 | Belgium | 30 Nov 2012 |
Phase 1/2 | 20 | tgmusotinh(rfvivpcogn) = ulrtgfijgf zplcekevow (rlwofonabi ) View more | Positive | 01 Sep 2019 |